Page 3 - Optimizing Outcomes News Today

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

A panel of medical experts open a discussion surrounding key treatment strategies in management of hepatocellular carcinoma (HCC).

Ghassan Abou-Alfa, MD, MBA, and Mohamed Salem, MD, provide insights regarding potential clinical pathway-driven challenges associated with HCC management.

Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Investigators compared analog and human insulin and major outcomes in patients with type 2 diabetes receiving hemodialysis.

Investigators compared analog and human insulin and major outcomes in patients with type 2 diabetes receiving hemodialysis.

Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death. Investigators compared analog and human insulin and major outcomes in patients with type 2 diabetes receiving hemodialysis.

Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

/PRNewswire/ -- Dr. Kiya Movassaghi, Founder and Director of Movassaghi Plastic Surgery & Ziba Medical Spa in Eugene, Oregon, was recently chosen by his...

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.